We are live on ! Find out more
ITP

Iron Triangle Partners Portfolio holdings

AUM $875M
1-Year Est. Return 49.85%
This Fund
S&P 500
This Quarter Est. Return
+10.48%
1 Year Est. Return
+49.85%
3 Year Est. Return
+151.9%
5 Year Est. Return
+239.84%
10 Year Est. Return
–
AUM
$722M
AUM Growth
-$262M
Cap. Flow
-$303M
Cap. Flow %
-41.97%
Top 10 Hldgs %
64.42%
Holding
39
New
13
Increased
2
Reduced
10
Closed
14

Top Buys

Rank Stock Value
1
MEDP icon
Medpace
MEDP
+$73.3M
2
ILMN icon
Illumina
ILMN
+$54.3M
3
THC icon
Tenet Healthcare
THC
+$46.7M
4
NVST icon
Envista
NVST
+$38.1M
5
MMSI icon
Merit Medical Systems
MMSI
+$23.2M

Top Sells

Rank Stock Value
1
EW icon
Edwards Lifesciences
EW
+$67.2M
2
DXCM icon
DexCom
DXCM
+$66M
3
MCK icon
McKesson
MCK
+$53.8M
4
ABBV icon
AbbVie
ABBV
+$48.8M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$45.7M

Sector Composition

Rank Sector Weight
1 Healthcare 98.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MEDP icon
1
Medpace
MEDP
$16.5B
$64.4M 8.92%
+192,842
New +$73.3M
ELAN icon
2
Elanco Animal Health
ELAN
$12.7B
$62.6M 8.68%
4,263,343
+1,034,904
+32% +$14.4M
ILMN icon
3
Illumina
ILMN
$28.7B
$57.4M 7.95%
+440,000
New +$54.3M
THC icon
4
Tenet Healthcare
THC
$21B
$51.3M 7.11%
+308,940
New +$46.7M
ACHC icon
5
Acadia Healthcare
ACHC
$2.99B
$50.9M 7.05%
802,151
-36,924
-4% -$2.67M
NVST icon
6
Envista
NVST
$4.34B
$43.3M 5.99%
+2,189,369
New +$38.1M
ISRG icon
7
Intuitive Surgical
ISRG
$128B
$35.4M 4.9%
72,001
-48,985
-40% -$22.8M
TEVA icon
8
Teva Pharmaceuticals
TEVA
$36.2B
$35M 4.85%
1,943,790
-1,356,395
-41% -$23.7M
OSCR icon
9
Oscar Health
OSCR
$8.54B
$34.2M 4.74%
1,611,909
-220,347
-12% -$3.97M
DHR icon
10
Danaher
DHR
$138B
$30.6M 4.24%
110,000
-77,011
-41% -$20.4M
GKOS icon
11
Glaukos
GKOS
$8.92B
$28.4M 3.93%
217,674
-290,482
-57% -$36.1M
EXAS
12
DELISTED
Exact Sciences
EXAS
$27.2M 3.77%
+399,871
New +$22.6M
PODD icon
13
Insulet
PODD
$11.4B
$25.6M 3.55%
110,000
-154,041
-58% -$31.6M
MMSI icon
14
Merit Medical Systems
MMSI
$4.54B
$25M 3.46%
+253,000
New +$23.2M
TWST icon
15
Twist Bioscience
TWST
$5.39B
$23M 3.19%
510,000
-16,455
-3% -$783K
AXSM icon
16
Axsome Therapeutics
AXSM
$12.3B
$22.7M 3.14%
+252,266
New +$22M
GERN icon
17
Geron
GERN
$949M
$15.2M 2.11%
+3,351,000
New +$15.2M
SNY icon
18
Sanofi
SNY
$105B
$15.1M 2.09%
+261,741
New +$14.1M
BKD icon
19
Brookdale Senior Living
BKD
$3.69B
$14.9M 2.07%
2,197,578
-3,604,363
-62% -$25.7M
INSM icon
20
Insmed
INSM
$22.7B
$13.1M 1.82%
180,000
-233,196
-56% -$17.2M
ACAD icon
21
Acadia Pharmaceuticals
ACAD
$4.35B
$11.5M 1.6%
+750,000
New +$12.5M
MYGN icon
22
Myriad Genetics
MYGN
$515M
$11M 1.52%
+401,859
New +$10.9M
ELAN icon
23
CALL
Elanco Animal Health
ELAN
$12.7B
$10.6M 1.47%
723,600
+62,800
+10% +$875K
INDV icon
24
Indivior Pharmaceuticals
INDV
$4.73B
$8.24M 1.14%
+845,470
New +$9.9M
BCAX
25
Bicara Therapeutics
BCAX
$1.83B
$5.09M 0.71%
+200,000
New +$5.1M
1
2

Similar funds

8KM
8 Knots Management Dallas, Texas $868M AUM 30.97% 1-Year Est. Return
MFG
MidWestOne Financial Group Iowa City, Iowa $900M AUM 23.95% 1-Year Est. Return
NP
Ninepoint Partners Toronto, Ontario, Canada $904M AUM 39.64% 1-Year Est. Return
GGI
Galaxy Group Investments New York $843M AUM 47.48% 1-Year Est. Return
WFAL
Wedbush Fund Advisers, LLC Pasadena, California $967M AUM
OBWP
O'Brien Wealth Partners Waltham, Massachusetts $756M AUM 13.93% 1-Year Est. Return
TWM
Tolleson Wealth Management Dallas, Texas $693M AUM 17.6% 1-Year Est. Return
AGC
Angelo Gordon & Co New York $1.06B AUM 47.95% 1-Year Est. Return

Iron Triangle Partners's Q3 2024 Portfolio in Review

As of Q3 2024, Iron Triangle Partners held 39 positions worth $722M, down 27% from $984M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Iron Triangle Partners withdrew a net $303M in Q3 2024, closing 14 positions and reducing 10 holdings. Its most notable exit was Edwards Lifesciences, an estimated $67.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 97% a quarter earlier.

Against the trend, Iron Triangle Partners opened a new position in Medpace worth $64.4M.

  • Iron Triangle Partners's largest Q3 2024 buy was Medpace: 192,842 shares worth $64.4M.
  • Iron Triangle Partners added most to Elanco Animal Health in Q3 2024, an estimated $14.4M increase.
  • Iron Triangle Partners's biggest Q3 2024 reduction was Glaukos, cutting an estimated $36.1M.
  • Iron Triangle Partners fully exited Edwards Lifesciences in Q3 2024, selling an estimated $67.2M.
  • Iron Triangle Partners's ten largest holdings make up 64% of its $722M portfolio in Q3 2024.
  • Iron Triangle Partners opened 13 new positions and closed 14 in Q3 2024.
  • Iron Triangle Partners's portfolio value fell 27% quarter-over-quarter to $722M.

Based on Iron Triangle Partners's 13F filing for Q3 2024, filed 14 Nov 2024.